Related Experiment Video

Updated: Jul 24, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like

Andrew P Gilmore1, Anthony J Valentijn, Pengbo Wang

  • 1School of Biological Sciences, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, United Kingdom. agilmore@man.ac.uk

The Journal of Biological Chemistry
|May 16, 2002
PubMed

Insights

A new cancer drug, ZD1839, effectively triggers cancer cell death (apoptosis) by blocking survival signals. This targeted approach activates the pro-apoptotic protein BAD, offering a novel therapeutic strategy for cancer treatment.

Area of Science:

  • Molecular oncology
  • Cancer therapeutics
  • Cell signaling pathways

Background:

  • Novel cancer chemotherapeutics are needed to induce apoptosis via pro-apoptotic proteins.
  • Epidermal growth factor (EGF) and insulin-like growth factor (IGF) signaling pathways promote cell survival and are often activated in human tumors.
  • Targeting these growth factor pathways presents a potential therapeutic strategy for cancer.

Purpose of the Study:

  • To investigate the mechanism by which ZD1839, an epidermal growth factor receptor (EGFR) inhibitor, induces apoptosis in cancer cells.
  • To determine if ZD1839 can overcome survival signals mediated by EGF and IGF.
  • To explore the therapeutic potential of targeting growth factor-mediated survival pathways.

Main Methods:

  • Treatment of mammary epithelial cell lines and primary cultures with ZD1839.
  • Analysis of apoptosis induction and mechanism of action.
  • Investigation of the role of the pro-apoptotic protein BAD and mitogen-activated protein kinase (MAPK) phosphorylation.
  • Assessment of IGF transactivation of the EGF receptor.

Main Results:

  • ZD1839 potently induced apoptosis in various cancer cell models, including patient-derived samples.
  • The drug functions by activating the pro-apoptotic protein BAD, thereby preventing cell survival.
  • ZD1839 effectively blocked IGF-mediated phosphorylation of MAPK and BAD, demonstrating interference with cross-talk between growth factor pathways.

Conclusions:

  • Blockade of the EGF receptor with ZD1839 is a potent strategy for inducing cancer cell apoptosis.
  • Targeting the BAD phosphorylation pathway through growth factor receptor inhibition offers a novel therapeutic approach.
  • This mechanism provides an alternative to DNA-damaging chemotherapies, potentially with a different therapeutic window.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: